LITTLE KNOWN FACTS ABOUT ABBV-744 AS A POTENTIAL THERAPEUTIC OPTION FOR AGGRESSIVE CANCERS.

In Phase C, participants will acquire ABBV-744 and oral navitoclax. In Segment D, members will acquire ABBV-744 and ruxolitinib. Individuals will get treatment till disease progression or maybe the participants are not able to tolerate the study drugs.then promote H3K27Ac at this area. Chromatin hyperacetylation could enhance the accessibility in t